Overview
Thymic Protein A — an immune regulator that breaks new ground
TISF (T4 immune stimulating factor) is a substance produced
by the thymus gland and used by the body to regulate the immune
system. TISF can now be produced in thymus cell cultures,
extracted, purified, freeze-dried, and packaged as a supplement
called ‘Thymic Protein A’. The inventor of this process, Terry
Beardsley, describes the protein in his 1997 patent (US #5,616,554)
as an “…immune potentiator which stimulates mature T
lymphocytes and thus enhances the response of animals, especially
mammalian
organisms, to infectious agents and to malignancies.”
Studies of the oral formulation have reported benefits for
- stimulating flagging immune systems (as in HIV disease)
- down-regulating overactive immune systems (as in allergic conditions)
- reducing viral activity in Epstein-Barr virus (EBV) infections — the virus involved in mononucleosis, Burkitt’s lymphoma,
nasopharyngeal carcinoma, aplastic anemia, and Hodgkin lymphoma
- reducing symptoms of chronic fatigue syndrome.
Thymic Protein A might also be used to good effect in auto-immune conditions, such as arthritis, asthma, allergy, lupus, and
some forms of diabetes.
Read Thymic Protein A Monograph
TISF
(T4 immune stimulating factor) is a substance produced by the thymus
gland and used by the body to regulate the immune system. TISF can now
be produced in thymus cell cultures, extracted, purified, freeze-dried,
and packaged as a supplement called ‘Thymic Protein A’. The inventor of
this process, Terry Beardsley, describes the protein in his 1997 patent
(US #5,616,554) as an “…immune potentiator which stimulates mature T
lymphocytes and thus enhances the response of animals, especially
mammalian organisms, to infectious agents and to malignancies.”
Thymic Protein A has been tested (by
injection) in various mammalian species, including humans. Several
small human studies of the oral formulation have also been carried out,
with benefits reported both for stimulating flagging immune systems (as
in HIV disease) and for down-regulating overactive immune systems (as
in allergic conditions). In patients with Epstein-Barr virus (EBV)
infections and with chronic fatigue syndrome, Thymic Protein A reduced
viral activity, reduced symptoms, and elevated the levels of T-cell
types whose depletion is characteristic of such infections. (EBV is
thought to be involved in a number of ailments, including chronic
fatigue syndrome, mononucleosis, Burkitt’s lymphoma, nasopharyngeal
carcinoma, aplastic anemia, and Hodgkin lymphoma.) Thymic Protein A
might also be used to good effect in auto-immune conditions, such as
arthritis, asthma, allergy, lupus, and some forms of diabetes.
Thymic Protein A is formulated to be
absorbed under the tongue. This is a new and still-developing
technology that evades the problems associated with other methods for
dosing proteins: degradation of the protein by digestive or lung
enzymes in the case of pill or inhaler formulations, and unpleasantness
and government interference in the case of injectable formulations. For
individuals whose oral absorption is inadequate, pretreatment of the
mouth with chitosan can enhance the permeability of the oral mucosa.
This product represents a potentially very
exciting advance in our ability to gain detailed control over our
bodies’ molecular-level processes — processes that so often go awry,
leaving us debilitated and frustrated.
